Deep-pocketed investors have adopted a bearish approach towards Gilead Sciences GILD, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in GILD usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Gilead Sciences. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 33% leaning bullish and 55% bearish. Among these notable options, 6 are puts, totaling $182,719, and 3 are calls, amounting to $98,565.
What's The Price Target?
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $80.0 and $105.0 for Gilead Sciences, spanning the last three months.
Volume & Open Interest Development
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Gilead Sciences's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Gilead Sciences's significant trades, within a strike price range of $80.0 to $105.0, over the past month.
Gilead Sciences Call and Put Volume: 30-Day Overview
Noteworthy Options Activity:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| GILD | CALL | TRADE | BEARISH | 09/19/25 | $9.3 | $9.1 | $9.1 | $92.50 | $35.4K | 203 | 49 |
| GILD | PUT | SWEEP | NEUTRAL | 02/14/25 | $0.92 | $0.63 | $0.8 | $91.00 | $34.8K | 14 | 1.0K |
| GILD | CALL | TRADE | BULLISH | 01/15/27 | $22.05 | $21.95 | $22.05 | $80.00 | $33.0K | 126 | 15 |
| GILD | PUT | TRADE | BEARISH | 03/14/25 | $8.25 | $7.5 | $8.1 | $102.00 | $32.4K | 1.3K | 82 |
| GILD | PUT | TRADE | BEARISH | 03/14/25 | $7.75 | $7.2 | $7.75 | $102.00 | $31.0K | 1.3K | 460 |
About Gilead Sciences
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
After a thorough review of the options trading surrounding Gilead Sciences, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
Present Market Standing of Gilead Sciences
- Currently trading with a volume of 1,766,908, the GILD's price is down by -0.86%, now at $95.21.
- RSI readings suggest the stock is currently may be approaching overbought.
- Anticipated earnings release is in 1 days.
What Analysts Are Saying About Gilead Sciences
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $99.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access. * Maintaining their stance, an analyst from JP Morgan continues to hold a Overweight rating for Gilead Sciences, targeting a price of $115. * An analyst from RBC Capital downgraded its action to Sector Perform with a price target of $84.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Gilead Sciences options trades with real-time alerts from Benzinga Pro.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
